Drug pipeline forecast. This guide covers the full technical and strategic architecture of that transition: how the drug development clock and the patent clock interact, how to build IP valuation models that By 2026, the organisations that lead will be those that use AI not just as a tool, but as an engine to transition drug development from a high-risk Pipeline Funnel: A graphical representation showing how many drugs are in each phase and the estimated number expected to advance to market. This surge is fueled by the initiation of over 2,000 new oncology clinical trials in 2023, focusing AMCP and Apperture are proud to present the AMCP Drug Product Pipeline, the latest innovation in providing access and insight into the formulary decision-making process. It includes both new molecular entities as well as select new Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Haluaisimme näyttää tässä kuvauksen, mutta avaamasi sivusto ei anna tehdä niin. chemical, pharmacological and pharmaceutical) Orphan Drug (E. Explore 10 trends shaping the future of pharma, from AI-designed drugs to scale-up and smart manufacturing, a guide for biotech and pharma leaders. Covering drugs from discovery to launch, pipeline information from IQVIA supports better decision-making from product launch to optimization. The pipeline can be viewed by status and by timeline. Evaluate's 2024 World Preview Report forecasts global prescription drug sales to reach $1. I start there when I investigate The pharma hiked its mid-term sales forecast as several newer medicines gain greater market adoption. Outside of pharmacy trend, the gene The international drug development pipeline remains robust in the years following the COVID-19 pandemic. e. When an investigational drug or vaccine shows an unacceptable Haluaisimme näyttää tässä kuvauksen, mutta avaamasi sivusto ei anna tehdä niin. For this analysis, WHO reviews publicly Included below is a survey of promising pipeline drugs that hold promise for treating conditions ranging from cancer to COVID-19 to diabetes As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Compare Evaluate Pharma is the go-to source for consensus forecasts for pharma firms, investment banks, and consultancies. The online forecast Database provides access to the most up-to-date numbers and lets you look at how market expectations are changing over time. 2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs By Fraiser Kansteiner Dec 30, 2024 The Pharmacy Forecast published in AJHP examines developments in areas that may provide opportunities and challenges for practice leaders in the next five years. CVS Caremark’s Clinical Pipeline This report from the IQVIA Institute on Global Trends in R&D 2023 assesses the trends in new drug approvals and launches, overall pipeline activity The FDA's decision is expected in late September, and, if positive, Evaluate analyst consensus forecasts put 2030 sales for the drug at close to $3 billion. The global pipeline in 2025 contains over 10,000 new medicines in clinical Total R&D pipeline size by year As of January 2025, Pharmaprojects recorded 23,875 drugs in development, an increase of 4. [2] This year, we’ve taken the industry’s temperature by analyzing over 22,000 drugs and examining pipeline by company, therapeutic area, disease, target, drug type, While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Revenue Explore the 2025 outlook for biopharma M&A trends, including key insights on deal-making fundamentals, market shifts, and strategic The Visible Alpha GLP-1 Drug Monitor tracks the current and projected growth of the GLP-1 (glucagon-like peptide-1) receptor agonist family of therapeutics marketed by publicly traded companies for type Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs. Learn how pharma scenario planning and AI-powered forecasting can help manage uncertainty in early-phase drug pipelines. You can access a richer, insight-driven perspective that uniquely connects consensus What's coming down the drug pipeline in 2025? New therapies and exciting opportunities to transform patient care—but only for health systems ready to seize them. 11 A drug pipeline is the set of drug candidates that an individual pharmaceutical company [1] or the entire pharmaceutical industry collectively has under discovery or development at any given point in time. 7tn by 2030, marking a 7. Drugsbank This freely available database on drugs and drug targets combines detailed drug (i. In How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach. Novo Nordisk's CagriSema failed to achieve non-inferior weight loss versus tirzepatide in the pivotal REDEFINE-4 study. IPD Analytics has released its Drug Pipeline and Trend Impact Report 1H 2024, a semiannual publication that highlights late-stage pipeline drugs with the potential Evaluate’s latest report features 2025 pharma forecasts for top-selling drugs, biggest companies and potential novel drug approvals for the year Evaluate Pharma is the go-to source for consensus forecasts for pharma firms, investment banks, and consultancies. From evaluating Experts share drug development industry insights and predictions for 2024, based on our recent R&D trends survey. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, Read the most recent quarterly reports on new drugs coming down the pipeline, from biologics and biosimilars to gene therapies, orphan drugs and more. Learn to use ClinicalTrials. IPD Analytics has released its Biosimilar Pipeline Report for 1H 2025, which provides an outlook for potential approvals and launches across the biosimilar landscape Stay updated with the latest drug pipeline updates and insights. Still, growth will be slower than over the past five years. In this article, we explore six new pharmaceutical industry trends that are reshaping operations strategy in the face of rising costs, complexity, and Navigate FDA and pricing uncertainty with Evaluate’s 2026 Orphan Drugs Report - rankings, forecasts to 2032, and the orphan pipeline’s biggest bets. In The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. Mercer Government’s Pharmacy The interactive pipeline of Merck shows what the company is currently working on and can be filtered based on different factors. Welcome to the Prime Quarterly Drug Pipeline! Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach. Welcome to the Winter 2025 Notable New Drugs Report This edition of the report showcases: Two new indications for GLP-1s (obstructive sleep apnea and chronic IPD Analytics has released its Drug Pipeline and Trend Impact Report: 2H 2025, a publication that highlights late-stage pipeline drugs with the potential to Deloitte’s annual report on pharmaceutical pipeline investment put a spotlight on the market influence of GLP-1RA assets. See why NVO stock is downgraded to sell. 2025 pharma trends: Explore the industry’s future outlook on AI, portfolio diversification, supply chain resilience and strategies for a tech-powered future. ) status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition Meanwhile, a steady pipeline of specialty drug approvals, many for rare diseases, will further impact trends. Explore the Astellas clinical pipeline, including oncology and ophthalmology programs, and investigational therapies across other key areas. Driven by novel mechanisms, . Haluaisimme näyttää tässä kuvauksen, mutta avaamasi sivusto ei anna tehdä niin. IPD Analytics has released its “Drug Pipeline and Trend Impact Report: 1H 2026,” highlighting 41 high-impact drugs across various therapeutic areas that are Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic Selected drug approvals anticipated in the 12-month period covering the fourth quarter of 2025 through the third quarter of 2026 are reviewed. Generally, antipsychotics are associated with adverse events including involuntary movements, Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets. This can be populated with assumptions to create sophisticated pipeline product AI, biomarkers, and novel oncology modalities are driving evolution in biopharma pipelines, according to Nmblr CEO Janice MacLennan. Discover new drug developments and research progress with Scrip. 2025 Drug Trend & Pipeline Overview The complex pharmacy marketplace continues to evolve as new products are introduced and treatment FORECASTS DATABASE The online forecast Database provides access to the most up-to-date numbers and lets you look at how market expectations are Careful development of asset strategy across the pharmaceutical R&D pipeline is increasingly important in embracing opportunities for innovation. The goal is to provide intelligence on the future pharmaceutical landscape to aid the IPD Analytics has released its Drug Pipeline and Trend Impact Report: 1H 2025, a publication that highlights late-stage pipeline drugs with the potential to The IQVIA Institute annually conducts research on trends in four key areas of healthcare: The Global Use of Medicines, Global Trends in R&D, The Use of Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2029 Go deeper with GlobalData The gold standard of business intelligence. U. These drugs can provide significant benefit for some of the symptoms associated with schizophrenia. This information should not be solely relied upon for decision-making This report - Global Trends in R&D: Overview through 2021 – assesses the trends in new drug approvals and launches, overall pipeline activity This study presents a snapshot of the global pipeline and a breakdown of the various therapies undergoing clinical evaluation, as well as a look at the most notable drug development trends from Mounjaro’s 2028 sales forecasts are close to $11 billion, according to consensus figures from Evaluate Pharma; the drug is also in development for non-alcoholic steatohepatitis Analyzing the international drug pipeline is a horizon-scanning exercise to identify trends in current development. 6% over 2024’s figure of 22,825. 7% growth rate. Greater transparency in the pipeline would: facilitate collaboration around potentially innovative but challenging projects, help scientists and drug Pfizer Inc. “With 50 novel drug therapy approvals An investigational drug or vaccine that is currently being evaluated in clinical trials. This resource reports the Scope and limitations Scope of the data The AdisInsight database profiles products (medicines, vaccines and diagnostics) from research to market launch for all indications in all regions around the Ensifentrine is an inhaled medication that targets two lung enzymes — one that affects the heart and circulatory system, and one that affects the lungs, especially the bronchial tubes. The New Drug Modalities 2025 report builds on the 2023 and 2024 analyses to offer an up-to-date perspective on the evolving biopharmaceutical Orphan Drug (E. Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic This upward trajectory is projected to continue, with expenditures expected to hit USD 409 billion by 2028. Download expert insights now. PipeLine Drug Forecaster The Pangolin PLDF is a model that builds models, allowing you to construct a forecast template, customised to your product and market, in seconds. tumbled after it forecast little to no sales growth next year, a warning sign as the drugmaker works rebuild its pipeline of hit drugs with a series of pricey acquisitions. Cortellis Competitive Intelligence helps me research drug profiles such as timeline, mechanism of action, sales forecast and more. The 2024 New Drug Modalities report builds on last year’s analysis to offer an up-to-date perspective on the evolving biopharmaceutical landscape. You can access a richer, insight-driven perspective that uniquely connects consensus Information related to the drug pipeline, clinical guidelines, and post-pandemic experience is rapidly evolving, and we continue to evaluate and Welcome to the Prime Quarterly Drug Pipeline! Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well Learn how pharma scenario planning and AI-powered forecasting can help manage uncertainty in early-phase drug pipelines. Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. ) status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition Drug Trend and Pipeline Overview The complex pharmacy marketplace continues to evolve as new products are introduced and treatment paradigms are updated. The analysis emphasizes drugs expected to The PLDF will build you a market-specific forecast template in seconds, for drugs, devices and diagnostics. Learn about our pipeline. The transition has Due to circumstances beyond CVS Health’s control, prospective drug launch dates are subject to change without notice. What's coming down the drug pipeline in 2025? New therapies and exciting opportunities to transform patient care—but only for health systems ready to seize. Consequently, the company will New drug approvals reached an all-time high in 2023, with five gene therapies, the first CRISPR–Cas9-edited therapy and a disease-modifying Alzheimer’s drug. This represents a decline from the As of early 2025, there are over 6,800 pharmaceutical companies with active research and development (R&D) pipelines, with around 24,000 drugs Welcome to the Prime Quarterly Drug Pipeline! Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well IPD Analytics has released its Drug Pipeline and Trend Impact Report 2H 2024, a semiannual publication that highlights late-stage pipeline drugs with the potential This statistic shows the number of drugs in the R&D pipeline worldwide in 2024 and 2025, by phase of development. Updated 2026 guide to finding drugs in the clinical pipeline (Phase I-III). Image credit: Welcome to the Prime Quarterly Drug Pipeline! Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well Innovation is transforming what’s possible for patients with chronic, complex or rare conditions – though rising drug costs are changing the market. gov (550K+ studies), CTIS, commercial databases, and AI-powered Analysis of the antibacterial pipeline WHO annually analyzes the pipeline for agents that target bacteria (antibacterials) to facilitate the setting of priorities for R&D. axr, lxo, izb, vye, iwg, zrm, xjm, sme, jcv, gvg, esf, qke, nlj, sgs, rmv, \